Abatacept ๐
Always check the BNF entry for Abatacept for the most up-to-date dosing and safety advice.
Abatacept is a specialist drug used in inflammatory arthritis where standard DMARDs have failed.
โ๏ธ Mode of Action
- ๐ก๏ธ T-cell activation inhibitor.
- It is a soluble fusion protein: CTLA-4 linked to the Fc portion of IgG1 (CTLA4-Ig).
- Prevents co-stimulatory signalling needed for full T-cell activation โ dampens autoimmune inflammation.
๐ Indications
- ๐คฒ Moderate-to-severe Rheumatoid Arthritis (specialist use only).
- ๐งด Psoriatic Arthritis (specialist use only).
๐ Dosing (must always check BNF or product literature)
| Regimen |
Notes (Dose, Frequency, Route) |
| Adults โค60 kg |
500 mg โ IV โ every 2 weeks ร3 doses, then every 4 weeks |
| Adults 60โ100 kg |
750 mg โ IV โ every 2 weeks ร3 doses, then every 4 weeks |
| Adults โฅ101 kg |
1000 mg โ IV โ every 2 weeks ร3 doses, then every 4 weeks |
| Subcutaneous |
125 mg once weekly โ SC โ review after 6 months if no response |
๐ก Response should be assessed at 6 months โ discontinue if ineffective.
๐ Interactions
- ๐ See BNF for full list.
- โ ๏ธ Risk of infection โ with other immunosuppressants.
โ ๏ธ Cautions
- ๐งซ Screen for latent infections (e.g. TB, hepatitis) before treatment.
- ๐ถ Effective contraception required during therapy and until 14 weeks after last dose.
- ๐ Vaccinations: avoid live vaccines during treatment.
๐ซ Contraindications
- โ Severe or uncontrolled infection.
๐ฅ Side Effects
- ๐คง Respiratory: cough, URTIs.
- ๐ GI: nausea, diarrhoea, vomiting, oral ulceration, abdominal discomfort.
- ๐ค Headache, dizziness, hypertension.
- ๐ฆ Increased risk of infection.
- ๐ธ Skin reactions and rashes.
๐ References